IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEP J

ECH CENTRAL

nlicant(s)

U.S. Serial No.

10/080,101

Filed

February 19, 2002

For

SYNTHETIC VACCINE AGENTS

Examiner

To Be Assigned

Art Unit

1645

745 Fifth Avenue New York, NY 10151

674542-200

EXPRESS MAIL

Mailing Label Number:

EV073654658US

Date of Deposit:

September 6, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington, D.C. 20231.

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

The Examiner's attention is respectfully drawn to the enclosed documents listed on the accompanying PTO form 1449.

Also enclosed is a copy of the International Search Report for the corresponding PCT application (PCT/DK02/00112), which was mailed on March 9, 2002. A copy of each of the references cited therein is enclosed.

As this Information Disclosure Statement is being filed before the mailing of the first Office Action, it is believed that no fee is required for entry of this paper. However, the

Commissioner is hereby authorized to charge any such fee, or credit any overpayment to Deposit Account 50-0230.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

Applicants respectfully request that the Examiner considers and makes of record the documents cited herewith and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

Attorneys for Applicants

By:

Thomas J. Kówalski Reg. No. 32,147 (212) 588-0800

					ATTY, DOCKET NO.		SEPRI NO	7	Sheet 1	
SEP 0 6 2002					·		Con Service Se			
					674542-2003		19/080,101			
					ATTY. DOCKET NO. 674542-2003 APPLICANT NIELSEN et al. FILING DATE Sheet GROUP					
						SEN et al. 2 6				
					FILING DATE		GROUP 9			
					February 19, 2002			GH45		
PADEMA					U.S. PAT	ENT DOCUMENTS				
XAMINER INITIAL		DOCU	MENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	
	AA	US 5,87	4,469	2/23/99	Maniar	et al.				
	AB	US 4,60	8,251	8/26/86	Mia					
	AC	US 4,60	1,903	7/22/86	Frasch					
AD		US 4,59	9,231	7/8/86	Milich	et al.				
	AE US 4,599,230 7/8/86 AF US 4,596,792 6/24/86 AG US 4,578,770 3/25/86		Milich	et al.						
			6/24/86	Vyas						
			Mitani							
	AH									
	AI									
	AJ			4				10		
	AK									
				1	FOREIGN	PATENT DOCUMENTS				
	·	DOCUMENT NUMBER		DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATIO	
									YES	NO
	AL	WO 95/05849		3/2/95	WIPO				<u> </u>	
	AM WO 94/03530 02/17/94 AN WO 00/20027 04/13/00		02/17/94	WIPC					ļ	
			WIPC)			<u> </u>			
	AO	WO 95	WO 95/07707 3/23/95		WIPC)				
	AP	WO 00	110 00/03030		WIPC)		<u>_l</u>	1	<u> </u>
						ing Author, Title, Date, Pertinent				
	AQ	Gregorius and Theisen, "In Situ Deprotection: A method for Covalent Immobilization of Peptides with well-defined orientation immunoassays such as enzyme-linked immunosorbent assay" (2001) Analytical Biochemistry 299: 84-91						vell-defined orientation	for use in solid	phase
	AR					complexes): The first decade" In				
	AC		Gosselin et al "Ful	anced Antigen Pro	esentation u	sing Human Fc□ Receptor (Mon	ocyte/Macrophage)-s	pecific immunogens" (1992) 149:3477	7-3481

Nilsson and Mosbach (1987) "Supports for Enzyme Immobilization" Methods in Enzymology 135: 67

Morein et al. "Immunostimulating Complexes, Clinical Potential in Vaccine Development" Clin. Immunotherapy (1995) 3(6):460-475

DATE CONSIDERED

Hermansson et al. "Immobilized affinity ligand techniques" (1992) 87.

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ΑT

ΑU

ΑV

EXAMINER

•					•	•		4	R	Sheet 2 of 2	
Based on Form PTO-1449						ATTY, DOCKET NO.		SERIADIO.			
(3/90)						674542-2003	SEN et al.				
100	LIST OF I	REFEREN	NCES CITED BY APPL	ICANT		APPLICANT		THE BEST			
10116	· 40.	Use sever	ral sheets if necessary)			NIELSEN et al.					
ero o co	M2 25					FILING DATE GROUP					
SEP 0 0 Z	WILL SE					February 19, 20	1645				
· ·	· O. C. /					repruary 19, 2002					
TRADEV				FO	DEICNID	ATENT DOCUMENTS					
						COUNTRY CLASS SUBCLASS TRANS					
		DOCUMENT NUMBER		DATE	_		CLASS	SOBCLASS	TICAL SI	ZATION	
	AW	WO 00/05316		2/3/00		WIPO					
	AX	WO 98		6/4/98							
	AY	WO 93/15760		8/19/93	WIPO						
	AZ	WO 93/23076		11/25/93	WIPO				- 1		
							 	<u> </u>			
		<u> </u>					<u> </u>				
	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) BA Irving et al. "Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics" Current									urrent	
			Opinion in Chemical Biology (2001) 5:314-324								
	BB		Parker and Tomer, "Epitope Mapping by a Combination of Epitope Excision and MALDI-MS" Methods in Molecular Biology, 146: 184-201								
	BC		Nelson et al. "Monoclonal antibodies" Molecular Pathology, Accepted for publication February 8, 2000								
	BD		Nussinov and Wolfson, "Efficient Computational Algorithms for Docking and for generating and matching a library of functional epitopes II. Computer Vision-based techniques for the generation and utilization of functional epitopes. (1999) Combinatorial Chemistry and High Throughut Screening 2: 261-269.								
	BE		Rothbard and Taylor, "A sequence pattern commin to T cell epitopes"93-100								
	BF		De Groot et al. "From genome to vaccine: in silico predictions, ex vivo verification" Vaccine 19 (2001) 4385-4395.								
	BG		Rammensee et al. "MHC ligands and peptide motifs: first listing" Immunogenetics (1995) 41: 178-228.								
	ВН		Schirle et al. "Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach" Eur. J. immunol, (2000) 30: 2216-2225								
	ВІ		Southwood et al. "Several Common HLA-DR Types share largely overlapping peptide binding repertoires" The Journal of Immunology, 1998, 160: 3363-3373.								
	вЈ		Singigaglia et al. "A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules" Nature Vol. 336 22/29 December 1988, 778-780								
	BK		Chicz et al. "Specificity and Promiscuity among naturally processed peptides bound to HLA-DR Alleles" (1993) J. Exp. Med. 178: 27-79								
	BL		Hammer et al. "Promiscuous and Allele-specific anchors in HLA-DR-Binding Peptides" (1993) Cell, vol. 197-203								
	ВМ		Falk et al. "Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing and general rules" Immunogenetics (1994) 39: 230-242								
	BN		Alexander et al. "Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma" Thorax (1994) 49:1231-1233.								
	во		Dempsey et al. "C3d of complement as a molecular adjuvant: bridging innate and acquired immunity" (1996) Science 271: 348								
	BP		Lou and Kohler, "Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide" Nature Biotechnology (1998) 16: 458-462								
	BQ		Gregorius et al. "Hydrocoating: a new method for coupling biomolecules to solid phases" Journal of Immunological Methods (1995) 181: 65-73								
EXAMINER	<u>-</u> .					DATE CONSIDERED					
			nsidered, whether or not considered. Include co			ith MPEP 609. Draw line through munication to applicant.					